SI2556841T1 - Postopek za inhibiranje kostne resorpcije - Google Patents

Postopek za inhibiranje kostne resorpcije

Info

Publication number: SI2556841T1
Authority: SI; Slovenia
Prior art keywords: bone resorption; inhibiting bone; inhibiting; resorption; bone
Prior art date: 2007-09-17

Application number

SI200831663A

Other languages

English (en)

Inventor

Ian Desmond Padhi

Graham Richard Jang

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-17

Filing date

2008-09-17

Publication date

2016-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40371592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2556841(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-17 Application filed by Amgen Inc. filed Critical Amgen Inc.

2016-10-28 Publication of SI2556841T1 publication Critical patent/SI2556841T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Obesity (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Communicable Diseases (AREA)

SI200831663A 2007-09-17 2008-09-17 Postopek za inhibiranje kostne resorpcije SI2556841T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97302407P	2007-09-17	2007-09-17
EP12180292.0A EP2556841B9 (en)	2007-09-17	2008-09-17	Method for inhibiting bone resorption

Publications (1)

Publication Number	Publication Date
SI2556841T1 true SI2556841T1 (sl)	2016-10-28

Family

ID=40371592

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SI200831170T SI2195026T1 (sl)	2007-09-17	2008-09-17	Protitelesa proti sklerostinu
SI200832137T SI3085386T1 (sl)	2007-09-17	2008-09-17	Metoda zaviranja resorpcije kosti
SI200831663A SI2556841T1 (sl)	2007-09-17	2008-09-17	Postopek za inhibiranje kostne resorpcije
SI200832217T SI3725329T1 (sl)	2007-09-17	2008-09-17	Postopek zaviranja resorpcije kosti

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SI200831170T SI2195026T1 (sl)	2007-09-17	2008-09-17	Protitelesa proti sklerostinu
SI200832137T SI3085386T1 (sl)	2007-09-17	2008-09-17	Metoda zaviranja resorpcije kosti

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200832217T SI3725329T1 (sl)	2007-09-17	2008-09-17	Postopek zaviranja resorpcije kosti

Country Status (20)

Country	Link
US (7)	US8017120B2 (sl)
EP (5)	EP3085386B1 (sl)
JP (2)	JP5643094B2 (sl)
AR (2)	AR068471A1 (sl)
AU (1)	AU2008302313C1 (sl)
CA (2)	CA2699905C (sl)
CL (1)	CL2008002775A1 (sl)
CY (3)	CY1114961T1 (sl)
DK (4)	DK3085386T3 (sl)
ES (4)	ES2581754T3 (sl)
FI (1)	FI3725329T3 (sl)
HR (4)	HRP20240493T3 (sl)
HU (3)	HUE030168T2 (sl)
LT (3)	LT2556841T (sl)
MX (1)	MX2010002971A (sl)
PL (4)	PL2556841T3 (sl)
PT (4)	PT2556841T (sl)
SI (4)	SI2195026T1 (sl)
TW (2)	TWI526222B (sl)
WO (1)	WO2009039175A2 (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395511B1 (en)	1998-11-27	2002-05-28	Darwin Discovery, Ltd.	Nucleic acids encoding a novel family of TGF-β binding proteins from humans
EP1636270B1 (en)	2003-06-16	2016-07-20	UCB Pharma S.A.	Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
EP2094731A2 (en) *	2006-11-10	2009-09-02	UCB Pharma S.A.	Anti human sclerostin antibodies
WO2008061013A2 (en) *	2006-11-10	2008-05-22	Amgen Inc.	Antibody-based diagnostics and therapeutics
US8178099B2 (en)	2006-12-29	2012-05-15	Osteogenex Inc.	Methods of altering bone growth by administration of sost or wise antagonist or agonist
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009062152A1 (en) *	2007-11-09	2009-05-14	Washington University In St. Louis	Methods for measuring the metabolism of cns derived biomolecules in vivo
BRPI0819688A2 (pt) *	2007-12-14	2015-06-16	Amgen Inc	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
CA2721052C (en)	2008-04-11	2023-02-21	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
LT3757126T (lt)	2010-11-05	2025-12-10	Novartis Ag	Psoriazinio artrito gydymo būdas, panaudojant il-17 antagonistus
CN103328632A (zh)	2010-11-30	2013-09-25	中外制药株式会社	与多分子的抗原重复结合的抗原结合分子
EP2646053A4 (en) *	2010-12-02	2014-05-28	Univ Washington	COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS ASSOCIATED WITH AMYLOIDER PLAQUE
AU2012223358A1 (en)	2011-03-01	2013-09-05	Amgen Inc.	Sclerostin and DKK-1 bispecific binding agents
AU2012236962B2 (en)	2011-03-25	2017-05-11	Amgen Inc.	Anti-sclerostin antibody crystals and formulations thereof
EP2699261B1 (en) *	2011-04-19	2018-07-11	Amgen Inc.	Method for treating osteoporosis
WO2012149246A1 (en)	2011-04-29	2012-11-01	Novartis Ag	Methods of treating squamous cell carcinoma related applications
EP2739311B9 (en) *	2011-08-04	2018-09-19	Amgen Inc.	Method for treating bone gap defects
KR20140069133A (ko) *	2011-09-22	2014-06-09	엑셀리시스, 인코포레이티드	골다공증의 치료방법
EA202091676A1 (ru)	2011-12-28	2021-01-29	Эмджен Инк.	Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EP2869844B2 (en) *	2012-07-05	2023-06-21	UCB Pharma S.A.	Treatment for bone diseases
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014118705A1 (en)	2013-01-31	2014-08-07	Novartis Ag	Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
JP6679582B2 (ja)	2014-09-30	2020-04-15	ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎＵｎｉｖｅｒｓｉｔｙ	タウの動態測定
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
WO2018115879A1 (en)	2016-12-21	2018-06-28	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP7050335B2 (ja)	2016-12-21	2022-04-08	メレオバイオファーマ３リミテッド	骨形成不全症の処置における抗スクレロスチン抗体の使用
WO2018139623A1 (en)	2017-01-30	2018-08-02	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
KR20200138254A (ko) *	2018-03-30	2020-12-09	암젠 인크	C-말단 항체 변이체
GB201810746D0 (en)	2018-06-29	2018-08-15	Mereo Biopharma 3 Ltd	Use of sclerostin antagonist
CN111658821A (zh) *	2020-06-03	2020-09-15	深圳市百吉因生物科技有限公司	负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
TW202430215A (zh)	2022-12-14	2024-08-01	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	用於將治療劑遞送至骨之組成物和方法
WO2025000015A1 (en) *	2023-06-27	2025-01-02	Perron Institute for Neurological and Translational Science Limited	Antisense oligomer treatment for bone loss
WO2025212547A1 (en) *	2024-04-05	2025-10-09	Amgen Inc.	Methods of treating osteogenesis imperfecta

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en) *	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4411993A (en) *	1981-04-29	1983-10-25	Steven Gillis	Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) *	1981-10-19	1984-01-24	Laipply Thomas C	One piece alcohol preparation device
USRE32011E (en) *	1981-12-14	1985-10-22	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) *	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) *	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) *	1984-05-11	1986-01-09	Matter + Siegmann Ag, Wohlen	Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) *	1984-12-03	1990-02-20	Teijin Limited	Monoclonal antibody to human protein C
US4987071A (en)	1986-12-03	1991-01-22	University Patents, Inc.	RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de)	1987-12-15	1995-01-15	Gene Shears Pty Ltd	Ribozyme.
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en) *	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
US5244805A (en)	1989-05-17	1993-09-14	University Of Georgia Research Foundation, Inc.	Baculovirus expression vectors
US5177197A (en)	1990-02-27	1993-01-05	Ludwig Institute For Cancer Research	Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JP3218637B2 (ja) *	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
JP2958076B2 (ja) *	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) *	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) *	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
JPH04141095A (ja)	1990-10-02	1992-05-14	Chemo Sero Therapeut Res Inst	組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) *	1990-10-12	1991-12-03	Trustees Of The University Of Pennsylvania	Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en)	1990-10-22	1992-04-30	Fox Chase Cancer Center	Dna construct for providing rna therapy
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5795965A (en)	1991-04-25	1998-08-18	Chugai Seiyaku Kabushiki Kaisha	Reshaped human to human interleukin-6 receptor
US5807683A (en)	1992-11-19	1998-09-15	Combichem, Inc.	Combinatorial libraries and methods for their use
US5864027A (en) *	1993-06-07	1999-01-26	Genentech, Inc.	HIV envelope polypeptides
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5453492A (en) *	1993-07-28	1995-09-26	La Jolla Cancer Research Foundation	60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) *	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5605793A (en) *	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
WO1995030003A2 (en)	1994-04-29	1995-11-09	Creative Biomolecules, Inc.	Morphogenic protein-specific cell surface receptors and uses therefor
US5738996A (en)	1994-06-15	1998-04-14	Pence, Inc.	Combinational library composition and method
DE4427221A1 (de)	1994-08-01	1996-02-08	Gsf Forschungszentrum Umwelt	Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en)	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
US6057421A (en) *	1994-11-30	2000-05-02	Immpheron, Inc.	Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5723750A (en)	1995-01-12	1998-03-03	Vanderbilt University	Transgenic plants expressing disassembly deficient viral coat proteins
US5795587A (en) *	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) *	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
WO1996039486A1 (en) *	1995-06-05	1996-12-12	Human Genome Sciences, Inc.	Human ccn-like growth factor
US5738868A (en) *	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
BR9710811A (pt) *	1996-05-22	1999-08-17	Novopharm Biotech Inc	Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
US6133426A (en) *	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
US5989909A (en)	1997-09-26	1999-11-23	Millennium Biotherapeutics, Inc.	Huchordin and uses thereof
AU6959898A (en) *	1997-04-11	1998-11-11	David J. Grainger	Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6278039B1 (en)	1997-05-28	2001-08-21	Axys Pharmaceuticals, Inc.	C. elegans deletion mutants
EP1958962A3 (en)	1997-06-12	2013-05-01	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
US6075007A (en)	1997-07-17	2000-06-13	Regeneron Pharmaceuticals, Inc.	Modified noggin polypeptide and compositions
CA2297109A1 (en)	1997-08-01	1999-02-11	Genset	5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) *	1997-09-08	2004-11-09	The Public Health Research Institute Of The City Of New York, Inc.	HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6251588B1 (en)	1998-02-10	2001-06-26	Agilent Technologies, Inc.	Method for evaluating oligonucleotide probe sequences
GB9818881D0 (en) *	1998-08-28	1998-10-21	Glaxo Group Ltd	Compounds
US6544485B1 (en) *	2001-01-29	2003-04-08	Sharper Image Corporation	Electro-kinetic device with enhanced anti-microorganism capability
US6395511B1 (en) *	1998-11-27	2002-05-28	Darwin Discovery, Ltd.	Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) *	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
CA2361553A1 (en)	1999-01-29	2000-08-03	Zhenping Zhu	Antibodies specific to kdr and uses thereof
US6110462A (en)	1999-03-03	2000-08-29	The Scripps Research Institute	Enzymatic DNA molecules that contain modified nucleotides
EP1185642A2 (en)	1999-06-09	2002-03-13	Genentech, Inc.	Compositions and methods for the treatment of tumor
US6197592B1 (en)	1999-07-15	2001-03-06	Bio-Rad Laboratories, Inc.	Clinical control materials for detection of bone resorptive markers
JP4141095B2 (ja)	1999-10-29	2008-08-27	三洋電機株式会社	半導体装置とその製造方法
AU2001241968B2 (en)	2000-03-02	2005-09-15	Amgen Inc.	Chordin-like-2 molecules and uses thereof
MXPA02011808A (es)	2000-06-01	2003-04-10	Amgen Inc	Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
US20040132021A1 (en)	2000-06-19	2004-07-08	Wendy Balemans	Osteolevin gene polymorphisms
CA2421056A1 (en)	2000-09-01	2002-03-28	Genentech, Inc.	A polypeptide for use as a diagnostic marker for the presence of colon tumours
ES2332402T5 (es)	2000-10-12	2018-05-14	Genentech, Inc.	Formulaciones de proteína concentradas de viscosidad reducida
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) *	2001-03-13	2002-09-13	The Minister Of National Defence	Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) *	2001-09-17	2003-04-10	Bayer Cropscience Ag	DELTA·1·-Pyrroline
US7261892B2 (en)	2001-11-27	2007-08-28	Celltech R&D Limited	Methods for diagnosis and treatment of epithelial-derived cancers
AU2002357107B2 (en)	2001-12-06	2008-01-10	Biocontrol Systems, Inc.	Sample collection and testing system
US20030186915A1 (en) *	2002-02-11	2003-10-02	Yang Pan	Regulatory polynucleotides and uses thereof
EP1575481A4 (en)	2002-03-01	2010-01-06	Celltech R & D Inc	PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
WO2003087763A2 (en)	2002-04-03	2003-10-23	Celltech R & D, Inc.	Association of polymorphisms in the sost gene region with bone mineral density
FR2838379B1 (fr)	2002-04-12	2005-06-24	Valeo Climatisation	Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
WO2003106657A2 (en)	2002-06-14	2003-12-24	Stowers Institute For Medical Research	Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) *	2003-06-16	2011-02-22	Stowers Institute For Medical Research	Antibodies that specifically bind SOST peptides
CA2504493C (en)	2002-11-01	2015-12-29	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
DK2284266T3 (da)	2002-11-14	2014-01-13	Thermo Fisher Scient Biosciences Inc	sIRNA-MOLEKYLE MOD TP53
DE10255152A1 (de)	2002-11-26	2004-06-03	Von Langen Ursula Lang	Schadstoffsauger
US7642238B2 (en) *	2002-12-05	2010-01-05	Shaughnessy John D	Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) *	2003-01-15	2004-07-22	Rajiv Doshi	System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
PL378566A1 (pl)	2003-03-14	2006-05-02	Celltech R & D, Inc.	Ligandy dla białek wiążących TGF-beta i ich zastosowania
EP1608733B1 (en)	2003-04-02	2011-12-07	Dharmacon, Inc.	Modified polynucleotides for use in rna interference
US20050158303A1 (en)	2003-04-04	2005-07-21	Genentech, Inc.	Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es)	2003-04-23	2009-08-04	Centro Inmunologia Molecular	Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1636270B1 (en)	2003-06-16	2016-07-20	UCB Pharma S.A.	Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en)	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
US20070269889A1 (en)	2004-02-06	2007-11-22	Dharmacon, Inc.	Stabilized siRNAs as transfection controls and silencing reagents
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050267233A1 (en)	2004-05-25	2005-12-01	Joshi Ashok V	Anti-microbial handle system
MX2007001221A (es)	2004-08-04	2007-03-23	Amgen Inc	Anticuerpos para proteina dickkopf-1 (dkk-1).
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
EP1981910B1 (en) *	2006-01-13	2013-06-26	A Chan Holding B.V.	Method for identifying inhibitor of the glypican-sclerostin interaction
EP2094731A2 (en)	2006-11-10	2009-09-02	UCB Pharma S.A.	Anti human sclerostin antibodies
WO2008061013A2 (en)	2006-11-10	2008-05-22	Amgen Inc.	Antibody-based diagnostics and therapeutics
US20080120672A1 (en)	2006-11-21	2008-05-22	Francesco Caggioni	Methods and Apparatus for Weighted Multicasting of Data Streams
US8178099B2 (en)	2006-12-29	2012-05-15	Osteogenex Inc.	Methods of altering bone growth by administration of sost or wise antagonist or agonist
JP2010526766A (ja)	2007-02-02	2010-08-05	ノバルティスアーゲー	骨関連障害を処置するためのスクレロスチン結合パートナーのモジュレーター
CN101646457B (zh) *	2007-03-20	2013-05-01	伊莱利利公司	抗硬骨素抗体
JOP20080381B1 (ar)	2007-08-23	2023-03-28	Amgen Inc	بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009056634A2 (en)	2007-11-02	2009-05-07	Novartis Ag	Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
BRPI0819688A2 (pt)	2007-12-14	2015-06-16	Amgen Inc	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
BRPI0913406A2 (pt)	2008-06-03	2018-01-09	Abbott Lab	imunoglobulinas de domínio variável duplo e usos das mesmas
WO2010100200A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Lyophilised antibody formulation
WO2010100179A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
WO2010115932A1 (en)	2009-04-08	2010-10-14	Novartis Ag	Combination for the treatment of bone loss
WO2010130830A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery
EP2632951B1 (en)	2010-10-27	2017-08-02	Amgen Inc.	Dkk1 antibodies and methods of use

2008
- 2008-09-16 CL CL2008002775A patent/CL2008002775A1/es unknown
- 2008-09-17 TW TW097135666A patent/TWI526222B/zh active
- 2008-09-17 WO PCT/US2008/076679 patent/WO2009039175A2/en not_active Ceased
- 2008-09-17 PL PL12180292.0T patent/PL2556841T3/pl unknown
- 2008-09-17 EP EP16162068.7A patent/EP3085386B1/en not_active Revoked
- 2008-09-17 SI SI200831170T patent/SI2195026T1/sl unknown
- 2008-09-17 DK DK16162068.7T patent/DK3085386T3/da active
- 2008-09-17 EP EP12180292.0A patent/EP2556841B9/en not_active Revoked
- 2008-09-17 PT PT121802920T patent/PT2556841T/pt unknown
- 2008-09-17 PL PL16162068T patent/PL3085386T3/pl unknown
- 2008-09-17 SI SI200832137T patent/SI3085386T1/sl unknown
- 2008-09-17 JP JP2010525108A patent/JP5643094B2/ja active Active
- 2008-09-17 LT LTEP12180292.0T patent/LT2556841T/lt unknown
- 2008-09-17 ES ES12180292.0T patent/ES2581754T3/es active Active
- 2008-09-17 DK DK08832690.5T patent/DK2195026T3/da active
- 2008-09-17 SI SI200831663A patent/SI2556841T1/sl unknown
- 2008-09-17 CA CA2699905A patent/CA2699905C/en active Active
- 2008-09-17 CA CA3170836A patent/CA3170836A1/en active Pending
- 2008-09-17 PT PT201743101T patent/PT3725329T/pt unknown
- 2008-09-17 HU HUE12180292A patent/HUE030168T2/en unknown
- 2008-09-17 FI FIEP20174310.1T patent/FI3725329T3/fi active
- 2008-09-17 PT PT161620687T patent/PT3085386T/pt unknown
- 2008-09-17 HU HUE20174310A patent/HUE066466T2/hu unknown
- 2008-09-17 PT PT88326905T patent/PT2195026E/pt unknown
- 2008-09-17 PL PL08832690T patent/PL2195026T3/pl unknown
- 2008-09-17 DK DK12180292.0T patent/DK2556841T3/en active
- 2008-09-17 ES ES08832690.5T patent/ES2445792T3/es active Active
- 2008-09-17 EP EP23219258.3A patent/EP4335510A3/en active Pending
- 2008-09-17 LT LTEP20174310.1T patent/LT3725329T/lt unknown
- 2008-09-17 AU AU2008302313A patent/AU2008302313C1/en active Active
- 2008-09-17 LT LTEP16162068.7T patent/LT3085386T/lt unknown
- 2008-09-17 SI SI200832217T patent/SI3725329T1/sl unknown
- 2008-09-17 EP EP20174310.1A patent/EP3725329B1/en active Active
- 2008-09-17 PL PL20174310.1T patent/PL3725329T3/pl unknown
- 2008-09-17 HU HUE16162068A patent/HUE050653T2/hu unknown
- 2008-09-17 AR ARP080104044A patent/AR068471A1/es not_active Application Discontinuation
- 2008-09-17 MX MX2010002971A patent/MX2010002971A/es active IP Right Grant
- 2008-09-17 TW TW104134720A patent/TWI612972B/zh active
- 2008-09-17 HR HRP20240493TT patent/HRP20240493T3/hr unknown
- 2008-09-17 ES ES20174310T patent/ES2975587T3/es active Active
- 2008-09-17 DK DK20174310.1T patent/DK3725329T3/da active
- 2008-09-17 US US12/212,327 patent/US8017120B2/en active Active
- 2008-09-17 HR HRP20140153AT patent/HRP20140153T1/hr unknown
- 2008-09-17 EP EP08832690.5A patent/EP2195026B1/en active Active
- 2008-09-17 ES ES16162068T patent/ES2815677T3/es active Active
2011
- 2011-04-19 US US13/090,075 patent/US8440193B2/en active Active
- 2011-04-19 US US13/090,058 patent/US8329176B2/en active Active
2013
- 2013-04-11 US US13/860,954 patent/US9089553B2/en active Active
2014
- 2014-03-07 CY CY20141100183T patent/CY1114961T1/el unknown
- 2014-09-03 JP JP2014178609A patent/JP5764704B2/ja active Active
2015
- 2015-06-16 US US14/740,838 patent/US10273293B2/en active Active
2016
- 2016-07-14 HR HRP20160872TT patent/HRP20160872T1/hr unknown
- 2016-07-15 CY CY20161100685T patent/CY1117908T1/el unknown
2017
- 2017-10-27 AR ARP170103001A patent/AR109995A2/es unknown
2018
- 2018-11-14 US US16/191,068 patent/US11091537B2/en active Active
2020
- 2020-09-02 CY CY20201100823T patent/CY1123463T1/el unknown
- 2020-09-09 HR HRP20201438TT patent/HRP20201438T1/hr unknown
2021
- 2021-07-15 US US17/376,304 patent/US12421304B2/en active Active

Also Published As

Publication number	Publication date
CY1114961T1 (el)	2016-12-14
WO2009039175A2 (en)	2009-03-26
JP2010539190A (ja)	2010-12-16
US8017120B2 (en)	2011-09-13
LT3725329T (lt)	2024-03-25
HK1182017A1 (en)	2013-11-22
LT3085386T (lt)	2020-11-25
PT2556841T (pt)	2016-07-25
HRP20160872T1 (hr)	2016-09-23
EP2195026B1 (en)	2013-12-25
JP5643094B2 (ja)	2014-12-17
CY1123463T1 (el)	2022-03-24
US9089553B2 (en)	2015-07-28
EP2556841A1 (en)	2013-02-13
HUE030168T2 (en)	2017-05-29
US20150274817A1 (en)	2015-10-01
JP2015038076A (ja)	2015-02-26
EP2195026A2 (en)	2010-06-16
CL2008002775A1 (es)	2008-11-07
DK3085386T3 (da)	2020-09-28
HRP20201438T1 (hr)	2020-11-27
EP2556841B1 (en)	2016-05-11
CA2699905C (en)	2023-09-05
PL3085386T3 (pl)	2020-11-30
SI2195026T1 (sl)	2014-04-30
HUE050653T2 (hu)	2020-12-28
AU2008302313A1 (en)	2009-03-26
US8440193B2 (en)	2013-05-14
US20130287764A1 (en)	2013-10-31
PL3725329T3 (pl)	2024-06-10
CA3170836A1 (en)	2009-03-26
PT3725329T (pt)	2024-03-14
AR068471A1 (es)	2009-11-18
TW200930403A (en)	2009-07-16
TWI612972B (zh)	2018-02-01
US20110268730A1 (en)	2011-11-03
PT2195026E (pt)	2014-03-31
MX2010002971A (es)	2010-08-10
EP3725329B1 (en)	2024-01-31
ES2975587T3 (es)	2024-07-09
TWI526222B (zh)	2016-03-21
US20190100580A1 (en)	2019-04-04
PT3085386T (pt)	2020-09-15
US10273293B2 (en)	2019-04-30
CY1117908T1 (el)	2017-05-17
HRP20140153T1 (hr)	2014-04-25
JP5764704B2 (ja)	2015-08-19
ES2445792T3 (es)	2014-03-05
EP4335510A3 (en)	2024-06-26
HRP20240493T3 (hr)	2024-07-05
HUE066466T2 (hu)	2024-08-28
PL2195026T3 (pl)	2014-05-30
US20210340236A1 (en)	2021-11-04
CA2699905A1 (en)	2009-03-26
ES2581754T3 (es)	2016-09-07
DK2556841T3 (en)	2016-08-15
LT2556841T (lt)	2016-09-12
AU2008302313B2 (en)	2013-10-31
EP3085386A1 (en)	2016-10-26
US20090074763A1 (en)	2009-03-19
TW201622747A (zh)	2016-07-01
ES2815677T3 (es)	2021-03-30
AR109995A2 (es)	2019-02-13
EP3085386B1 (en)	2020-06-24
WO2009039175A3 (en)	2009-05-07
PL2556841T3 (pl)	2016-11-30
AU2008302313C1 (en)	2014-04-03
DK2195026T3 (da)	2014-03-03
EP2556841B9 (en)	2017-09-06
US20110262433A1 (en)	2011-10-27
EP3725329A1 (en)	2020-10-21
EP4335510A2 (en)	2024-03-13
SI3725329T1 (sl)	2024-04-30
US8329176B2 (en)	2012-12-11
US11091537B2 (en)	2021-08-17
DK3725329T3 (da)	2024-03-18
SI3085386T1 (sl)	2020-11-30
FI3725329T3 (fi)	2024-03-18
US12421304B2 (en)	2025-09-23

Publication	Publication Date	Title
LT2556841T (lt)	2016-09-12	Kaulų rezorbcijos slopinimo būdas
EP2367489A4 (en)	2013-05-29	CERCLAGE SYSTEM FOR BONE
IL198649A0 (en)	2010-02-17	Interspinous implant
EP2094350A4 (en)	2010-07-14	GROUPED ELECTRODES FOR BACKMARK STIMULATION
EP2079414A4 (en)	2011-12-28	SYSTEM FOR CHEMOHYPER THERMAL TREATMENT
IL211523B (en)	2018-04-30	Devices for increasing the density of jaw-skull bones
GB0707096D0 (en)	2007-05-23	Method
EP2171169A4 (en)	2013-07-31	METHOD
PL2002702T3 (pl)	2016-05-31	Sposób wstępnego kiełkowania materiału siewnego
GB0703366D0 (en)	2007-03-28	Method
GB2456999B (en)	2011-04-27	Method for preparing 2-deoxy-L-ribose
GB0708960D0 (en)	2007-06-20	Method
IL202261A0 (en)	2010-06-16	Method for pain control
GB0705321D0 (en)	2007-04-25	Method
EP2208733A4 (en)	2014-08-06	FOOD FOR INHIBITING BONE RESORPTION
GB0600228D0 (en)	2006-02-15	Inactivation method
ZA201002110B (en)	2010-11-24	Method for stabilizing quercetin
ZA200903242B (en)	2010-08-25	Treatment for multiple myeloma
PL1842931T3 (pl)	2014-07-31	Sposób obróbki cieplnej
GB0706833D0 (en)	2007-05-16	Method
HUP0800040A2 (en)	2009-06-29	Set for fixing bones
PL381143A1 (pl)	2008-05-26	Sposób otrzymywania 2-metyloglicydolu
GB0624469D0 (en)	2007-01-17	Cryptographically secure method
HU0700132V0 (en)	2007-09-28	Implantation for fixing bones
PL394170A1 (pl)	2011-06-20	Sposób mocowania fantomu